Robinson SM, Mann DA, Manas DM, Oakley F, Mann J, White SA. 

The potential contribution of tumour-related factors to the development of 
FOLFOX-induced sinusoidal obstruction syndrome. 

British Journal of Cancer 2013, 109(9), 2396-2403.

Copyright:

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Link to published article:

http://dx.doi.org/10.1038/bjc.2013.604

Date deposited: 2nd December 2014
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome

S M Robinson*,1,2, D A Mann2, D M Manas1, F Oakley2, J Mann2,3 and S A White1,2,3

1Department of HPB Surgery, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK and 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

Background: Chemotherapy-associated liver injury (CALI) has been linked to increased morbidity and poorer disease-specific outcomes in patients undergoing resection of colorectal liver metastases (CRLM). The aim of this study was to assess the contribution of tumour-related factors to the development of FOLFOX-induced liver injury.

Methods: We assessed the effect of FOLFOX treatment on the murine liver either in the presence or absence of CRLM to evaluate the contribution of both chemotherapy and tumour death to the development of CALI.

Results: In the presence of liver metastases, there was increased hepatic expression of plasminogen activator inhibitor-1 (146-fold; P<0.01) and vWF (2.4-fold; P<0.01) transcript as compared with sham-operated controls. In addition, we detected large clusters of megakaryocytes in the spleen of FOLFOX-treated tumour-bearing animals. The livers of FOLFOX-treated animals also showed changes in matrix remodelling genes such as TGFβ (P<0.01), MMP2 (P<0.001), TIMP1 (P<0.001) and Pro-Collagen I (P<0.05) which was exacerbated in the presence of tumour. These genes have previously been demonstrated to have a key role in FOLFOX-induced liver injury.

Conclusion: It appears that the toxicity of FOLFOX chemotherapy is enhanced by tumour-related factors.

Colorectal cancer is the second leading cause of cancer-related death in the western world. Up to 50% of patients with colorectal cancer will develop liver metastases and in 25% of patients are present at the time of primary diagnosis (Stangl et al, 1994). Resection is the gold standard treatment for colorectal liver metastases (CRLM) with 5-year survival in the order of 50–60% being achievable (Rees et al, 2008). Unfortunately a significant proportion of patients are not suitable for surgery at the time of presentation and require neoadjuvant chemotherapy for the aim of down-staging their disease such that they become operable. In those patients successfully down-staged long-term survival can be achieved which is comparable with those patients offered surgery from the outset (Alberts et al, 2005).

The most commonly used chemotherapy for CRLM consists of folinic acid/5-FU (or the oral pro-drug Capecitabine) in combination with either Oxaliplatin (FOLFOX) or Irinotecan (FOLFIRI) both of which have widely proven efficacy in down-staging CRLM (Robinson et al, 2009). Nonetheless these regimens are associated with the development of chemotherapy-associated liver injury (CALI). The nature of the injury appears to be regimen specific with FOLFIRI being associated with steatohepatitis, whereas FOLFOX is linked to the development of sinusoidal obstruction syndrome (SOS) and nodular regenerative hyperplasia (Robinson et al, 2009; Rubbia-Brandt et al, 2010). The presence of any underlying hepatic parenchymal disease increases the risk of post-operative hepatic insufficiency and as such the presence of CALI is...
a cause of major concern when undertaking more extensive resections (de Meijer et al, 2010). In addition, CALI has been linked to poorer long-term disease-specific outcomes (Tamandl et al, 2011).

Increasingly an ever more aggressive approach is being taken to the management of CRLM with increasing numbers of patients undergoing second and third resections for recurrent disease (Adam et al, 1997; Adam et al, 2003). Frequently these procedures are interspersed with repeated cycles of chemotherapy meaning that CALI is becoming an ever more pressing issue facing the surgeon managing this cohort of patients. Understanding the pathogenesis of this condition would enable the identification of therapeutic strategies to reduce the incidence of this complication of chemotherapy and thereby improve the safety of surgery in this cohort of patients.

Several authors have attempted to investigate the pathogenesis of this condition using human tissue obtained at the time of liver resection (Pilgrim et al, 2011; Rubbia-Brandt et al, 2011; Agostini et al, 2012). The limitation of this approach is that although it provides an understanding of the ultimate effect of chemotherapy administration on the liver, it does not enable one to investigate the biological mechanisms resulting in these changes or how their manipulation may impact on subsequent liver injury. To do this, a realistic in vivo experimental model is required which reflects, as closely as possible, the events occurring in patients. To this end, we recently developed a murine model of chemotherapy-induced liver injury which enabled us to identify a number of the key pathological processes involved in the pathogenesis of Oxaliplatin-induced SOS (Robinson et al, 2013).

Data from two cohort studies have suggested that tumour-related factors may contribute to the development of SOS (Soubrance et al, 2010; Tamandl et al, 2011). The aim of this study was to determine what impact tumour-related factors might have on Oxaliplatin-induced SOS.

**MATERIALS AND METHODS**

All animal studies were subject to review and approval by the local research ethics committee and the UK home office. The use of human tissue for research was approved by the NHS research ethics committee (reference 11/NE/0009 & 07/Q0906/15) and informed consent was obtained from all participants.

**In vitro chemotherapy model.** The MCA38 colorectal cancer cell line was a gift from Dr Mario Paolo Colombo (Istituto Tumori, Milan, Italy). Cells were cultured in Dulbecco’s modified eagle medium supplemented with 10% fetal calf serum, 100 U ml⁻¹ Penicillin, 100 µg ml⁻¹ Streptomycin and 2 mM L-Glutamine.

The IC₅₀ concentration of Oxaliplatin (7 µM) and 5-FU (14 µM) at 48 h were determined by MTT assay. When treating MCA38 cells with FOLFOX, they were seeded and allowed to adhere overnight before exchanging media for that supplemented with 10 µM folic acid. Oxaliplatin was then added followed by 5-FU 2 h later (Fischel et al, 2002).

**Hepatic tumour implantation.** C57Bl/6 mice were subject to laparotomy under isoflurane anaesthesia. In all, 1 × 10⁵ MCA38 cells stably transfected with the pGL4.51 luciferase reporting vector (Promega, Southampton, UK) were then injected beneath the capsule of the left lobe of the liver in 10 µl of Hanks buffered salt solution. Haemostasis was achieved by manual compression and the injection track sealed with butylcyanoacrylate glue (Indermil, Henkel Ltd, Hatfield, UK). Animals were allowed to recover for 5 days before the administration of chemotherapy. Sham-operated controls underwent laparotomy only.

The FOLFOX chemotherapy regimen consisted of weekly cycles of intraperitoneal (i.p.) FOLFOX consisting of 6 mg kg⁻¹ Oxaliplatin followed 2 h later by 50 mg kg⁻¹ 5-FU and 90 mg kg⁻¹ folic acid. This drug-dosing schedule was based upon a careful review of the literature and has been previously used within our unit to induce histological changes of SOS in C57BL/6J mice after 5 weeks of treatment. Control animals were treated with vehicle alone (Boughattas et al, 1989; Cao et al, 1996; Keizman et al, 2010; Robinson et al, 2013).

Tumour-bearing mice and sham-operated controls were treated with IP FOLFOX, or vehicle control, giving a total of four groups of animals (n = 6 per group). The treatment protocol had to be terminated one day after the third treatment owing to large tumour size in the control animals and significant weight loss in the FOLFOX-treated group.

Tumour size in culled animals was assessed using the tumour to body weight ratio (tumour weight/pre-mortem body weight) and by estimating the tumour volume (tumour width² × tumour length × 0.5).

**Patient tissue collection.** A 1-cm³ segment of non-tumour-bearing liver tissue was collected from patients undergoing elective liver resection and stored in RNA later (Sigma-Aldrich, Dorset, UK) prior to storage at − 80 °C. Biopsies were taken immediately after opening the abdomen prior to commencing parenchymal transaction or vascular inflow occlusion. Clinical data including the use of pre-operative chemotherapy were recorded for each patient. Histology reports from these patients were reviewed to identify those with evidence of vascular injury to the hepatic parenchyma in keeping with a diagnosis of SOS. Patients with underlying chronic liver disease or primary liver tumours were excluded from analysis.

Three groups of patients were identified for subsequent analysis – those who were chemotherapy naive (n = 10); those who received pre-operative Oxaliplatin-based chemotherapy but had no evidence of vascular injury (n = 9) and those who received pre-operative chemotherapy and had an identifiable vascular injury (n = 13).

**RNA extraction, cDNA synthesis and qRT–PCR.** Total RNA was extracted using the RNeasy purification system (Qiagen, Manchester, UK). One microgram of total RNA was used to generate cDNA using MMLV-RT and a random hexamer primer (Promega). Quantitative real-time PCR (qRT–PCR) was performed using SYBR-green reagents (Sigma-Aldrich). GAPDH was used as the internal control.

**Immunohistochemistry.** Sections were deparaffinised and endogenous peroxidase activity blocked. Following antigen retrieval, non-specific binding was inhibited by using the avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA, USA) followed by incubation for 30 min with 20% swine serum. Primary antibodies were added and sections incubated overnight at 4 °C. The following morning sections were washed then incubated with an appropriate biotin-conjugated secondary antibody for 2 h then washed and further incubated for 1 h with Streptavidin Biotin Peroxidase Complex (Vector Laboratories). Positive cells were visualised with 3,3′-diaminobenzidine tetrahydrochloride (DAB) (Vector Laboratories) and counterstained with haematoxylin. Sections were blinded and the number of positive cells was counted in 15 high-power fields (HPFs).

**CXCL1 ELISA/extracellular ATP assay cell culture supernatants.** Supernatant was harvested from MCA38 cells treated with FOLFOX chemotherapy, or vehicle control, for 24 h and snap frozen at − 80 °C. CXCL1 was measured in the cell culture supernatants using a CXCL1 DuoSet ELISA Development Kit (R&D Systems, Abingdon, UK).

**Statistical analysis.** Numerical data are expressed as mean value ± s.e.m. Statistical significance was assessed using
Mann–Whitney U-test and Kruskall–Wallis one-way analysis of variance as appropriate for in vivo data. A two-tailed Student’s t-test was used for in vitro qRT–PCR data. A P-value of <0.05 was considered to be statistically significant.

RESULTS

FOLFOX treatment of colorectal tumour cells activates inflammatory signalling. Recent reports have suggested that cancer cell death by Oxaliplatin-induced apoptosis may not be inflammatory signalling. To explore whether these tumour-produced mediators might contribute to Oxaliplatin-induced liver injury, it was decided to establish experimental CRLM in C57/Bl6 mice with the syngeneic MCA38 colorectal cell line.

Prior to in vivo studies, death of MCA38 cells in response to FOLFOX was confirmed in vitro (Figure 1A). In addition, it was observed that FOLFOX-induced expression of chemokines associated with inflammation and wound-repair responses (Figure 1B). A greater than 30-fold increase in CXCL1 transcript (the murine equivalent of IL-8) was confirmed by measuring a three-fold increase in secretion of soluble CXCL1 protein (Figure 1C). CXCL5, CCL2 and CCL5 chemokines were also induced by FOLFOX indicative of cell-damage-associated activation of inflammatory gene expression in the culture.

Figure 1. MCA38 cells were treated in vitro with FOLFOX. Cell death in response to FOLFOX after 48 h treatment was confirmed by propidium iodide staining (A). MCA38 cells treated with FOLFOX for 24 h show increased expression of the chemokines CXCL1, CXCL5, CCL2 and CCL5 (B). The increased expression of CXCL1 transcript was confirmed by ELISA (C). (*P < 0.05, **P < 0.01, ***P < 0.001).

We have previously reported that increased hepatic expression of these chemokines appears to be implicated in the pathogenesis of SOS in FOLFOX-treated C57Bl/6j mice (Robinson et al, 2013). It may be that their production of by apoptosing colorectal cancer cells within the liver contributes further to this process and it was elected to further test this hypothesis in vivo.

Combined tumour and FOLFOX therapy stimulates matrix remodelling. Preliminary experiments demonstrated that 5 days following hepatic implantation of 10⁵ MCA-38 cells, a solid tumour was detectable by IVIS imaging (Figure 2A) and on this basis this was the time point at which treatment with FOLFOX, or vehicle control, was commenced. The in vivo effectiveness of this chemotherapy regimen was demonstrated by a marked reduction in the tumour volume (Figure 2B, P = 0.063) and tumour to body weight ratio (Figure 2C, P = 0.041) in FOLFOX-treated animals. When untreated these tumours produced a large local mass arising from the liver parenchyma (Figure 2D and E) and in some animals lung metastases were detectable although this was a late event. Significant weight loss in both FOLFOX groups indicated systemic toxicity of the chemotherapy regimen (Figure 2F).

Neither H&E (Figure 2G) nor Reticulin (not shown)-stained sections of the liver demonstrated sufficient changes to fit the diagnostic criteria for SOS. We have previously demonstrated that 5 weeks of FOLFOX treatment is necessary in C57Bl/6j mice to induce histological changes of SOS and the absence of positive findings in this regard is not surprising (Robinson et al, 2013). Nevertheless, we elected to interrogate this model further to determine if molecular changes within the liver implicated in the pathogenesis of SOS were enhanced by the presence of tumour.

Matrix remodelling and the subsequent development of sinusoidal fibrosis is a cardinal feature of SOS. Hepatic stellate cells (HSCs) have pivotal roles in matrix remodelling, particularly in hepatic fibrogenesis. During this process, quiescent HSCs become activated whereby they take on a myofibroblast phenotype and express smooth muscle α-actin (αSMA) and procollagen I. Figure 3A shows that FOLFOX treatment of tumour-bearing mice results in up-regulation of αSMA (P = 0.082) and procollagen I (P = 0.009) transcripts when compared with sham-operated vehicle controls, in a manner similar to that seen with mice which developed the histological changes of SOS (Robinson et al, 2013). This fibrogenic state was supported by a modest increase in numbers of hepatic αSMA+ cells (7.1 ± 9.9 cells per HPF; P = 0.015) as detected by immunohistochemistry (Figure 3B). In order to confirm the relevance of increased αSMA in the pathogenesis of Oxaliplatin-induced SOS, we performed qRT–PCR on mRNA isolated from the non-tumour-bearing liver of patients undergoing resection of CRLM. In those patients with Oxaliplatin-induced vascular injury, we were able to demonstrate a significant increase in expression of αSMA as compared with those receiving Oxaliplatin who do not develop a vascular injury (P = 0.019; Figure 3C).

A similar pattern was seen in the hepatic expression of tissue inhibitor of metalloproteinases 1 (TIMP 1) transcript in tumour-bearing FOLFOX-treated mice (Figure 3D; P = 0.004) again in keeping with the process of matrix remodelling in SOS that we have previously reported. It appears that this response is, in part, driven by the master regulator TGFβ1, the transcript levels of which are maximally elevated in tumour-bearing animals treated with FOLFOX (Figure 3E; P = 0.004). FOLFOX treatment resulted in a 13-fold up-regulation of MMP2 in tumour-bearing animals treated with FOLFOX (P < 0.002), whereas no change in expression was detectable in sham-operated animals (Figure 3F).

Previous published data both from experimental animal studies and human microarray studies have suggested that FOLFOX-induced liver injury is associated with increased hepatic expression...
of angiogenic factors, in particular, VEGF-A and VEGF-C. (Rubbia-Brandt et al, 2011; Robinson et al, 2013). The presence of tumour itself was associated with a modest increase in hepatic expression of VEGF-C (1.7-fold, \( P = 0.002 \)), which was further increased upon treatment with FOLFOX (2.3-fold; \( P = 0.002 \)). It is noteworthy that FOLFOX treatment alone had no effect on VEGF-C expression (Figure 3G). In contrast to this, the presence of tumour within the liver had no effect on the hepatic expression of VEGF-A. Confirming the importance of angiogenesis in the pathogenesis of SOS, we were able to demonstrate increased

Figure 2. C57Bl/6 mice underwent either laparotomy alone (shams) or laparotomy with implantation of MCA38 cells beneath the liver capsule. After 5 days tumour was detectable with IVIS imaging (A). Three weekly doses of i.p. FOLFOX resulted in a reduced tumour mass as demonstrated by tumour volume (B) and tumour/body weight ratio (C). The tumour/liver interface is shown in (D) and typical gross appearances of the tumours in (E). FOLFOX-treated animals demonstrated significant weight loss as compared with controls (F). H&E stained sections (G) did not demonstrate histological changes of SOS. (* \( P < 0.05 \)).
expression of VEGF-C in patients with Oxaliplatin-induced vascular injury (Figure 3H; P = 0.044).

Combined tumour and FOLFOX results in a prothrombotic environment. Our previous work has demonstrated that activation of the clotting cascade seems to have a role in the pathogenesis of SOS (Robinson et al, 2013). As shown in Figure 4A, treatment of tumour-bearing mice with FOLFOX is associated with a 146-fold increase in expression of the pro-thrombotic plasminogen activator inhibitor-1 (PAI-1; SERPINE1) transcript (P = 0.004) as well as a more modest increase in expression of von Willebrand factor (P = 0.004; Figure 4B). There was a trend towards elevated VWF transcript in patients with Oxaliplatin-induced vascular injury although this did not quite reach statistical significance (P = 0.059; Figure 4C).

In keeping with previous reports, we were able to confirm that FOLFOX administration results in the accumulation of large clusters of megakaryocytes within the spleen of both sham-operated and tumour-bearing animals treated with FOLFOX (Figure 4D and E; P < 0.05).

**DISCUSSION**

Until the advent of modern chemotherapy regimens, the only recognised cause of SOS was the ingestion of pyrrolizidine alkaloids. SOS was subsequently recognised as a clinical entity in patients undergoing myeloablative chemotherapy prior to bone marrow transplantation and, more recently, following administration of platinum-based chemotherapy to patients with CRLM (DeLeve et al, 2002). Until recently knowledge regarding the pathogenesis of this disease was drawn predominantly from the study of rats treated with monocrotaline which results in rapid appearance of SOS-type lesions within the liver (DeLeve et al, 1999).

Although the administration of monocrotaline may replicate many of the histological changes seen in patients with CALI, it is extremely unlikely that the stimulus driving these changes is in any way similar. To address this, we have recently established a murine model of FOLFOX-induced SOS that replicates the histological changes seen in patients receiving this chemotherapy regimen. The aim of the current study was to evaluate the potential contribution of tumour-related factors to the development of SOS. Although on this occasion, we were not able to replicate the histological features of SOS, because of the need to terminate the model with due regards to animal welfare, we have demonstrated that many of the changes in gene expression associated with the development of this condition are accelerated in tumour-bearing mice (Rubbia-Brandt et al, 2011; Robinson et al, 2013).

One criticism of the current model may be that the route of chemotherapy administration (i.p.) differs from that used in patients and therefore may limit the development of histological
changes within the liver. This route was chosen as repeated intravenous administration of a compound to mice (e.g. via the tail vein) is not practical owing to the high failure rate with this technique and the need for animal restraint (Turner et al, 2011). It has been previously demonstrated that the i.p. administration of Oxaliplatin can lead to the development of neurotoxicity in mice suggesting there is significant systemic drug absorption (Ta et al, 2009). Moreover, we have recently reported that administration of i.p. FOLFOX to mice for 5 weeks does lead to the development of the histological features of SOS (Robinson et al, 2013).

Pro-thrombotic changes in the sinusoidal endothelium have been implicated in the development of SOS (Copple et al, 2002; Rubbia-Brandt et al, 2011; Robinson et al, 2013). In particular, elevated serum PAI-1 levels have been reported both in mice with FOLFOX-induced SOS as well as bone marrow transplantation patients who go on to develop SOS following myeloablative chemotherapy (Kaleelrahman et al, 2003; Robinson et al, 2013). The importance of this process is reflected in the relative success of the fibrinolytic agent defibrotide in the treatment of SOS in bone marrow transplant recipients (Benimetskaya et al, 2008). In concordance with these findings, we see increased expression of the PAI-1 and vWF genes in the liver of mice treated with FOLFOX chemotherapy, particularly in the presence of tumour.

It is likely that the presence of megakaryocytes in both the spleen and liver following FOLFOX treatment results in the release of platelets directly into the portal venous system and may contribute to the development of pro-thrombotic environment within the injured hepatic sinusoid. Given these observations, it may be that patients with particularly large tumours would benefit from treatment with antiplatelet therapy such as Aspirin which it has been suggested may reduce the incidence of SOS in Oxaliplatin-treated patients (Brouquet et al, 2009).

Despite the absence of florid fibrosis in our model, we have shown changes in gene expression in keeping with a classical fibrogenic response that we have previously reported in the context of FOLFOX-induced SOS (Robinson et al, 2013). It appears from the current study that the increase in expression of matrix remodelling genes is markedly exacerbated by the presence of tumour within the liver. It is increasingly recognised that tumour death in response to many cytotoxic agents is not a silent event but rather is associated with the production of a wide variety of mediators that are capable of producing an inflammatory response (Tesniere et al, 2008; Martins et al, 2009).

One example of how inflammatory mediator production by dying tumour cells may contribute to the development of SOS is provided by the chemokine CXCL1, the murine equivalent of IL-8.
which is abundantly produced by FOLFOX-treated MCA38 cells and is also elevated in the serum of patients with SOS (Remberger and Ringden, 1997; Schots et al., 2003). CXCL1 exerts its effect on endothelial cells via the CXCR2 receptor with resultant expression of genes involved in angiogenesis such as MMP2 and VEGF (Li et al., 2003; Li et al., 2005). In addition, IL-8 signalling to human endothelial cells may increase further expression of prothrombotic genes such as PAI-1 (Cheng et al., 2008). The observation that patients with a larger tumour burden are more likely to develop SOS, despite a similar number of cycles of chemotherapy, would seem to support the concept that tumour death contributes to SOS development (Tamandl et al., 2011). The ideal strategy for patients with CRLM receiving pre-operative FOLFOX-based chemotherapy would be to administer a drug for the duration of the chemotherapy that prevents the development of SOS. The use of antioxidants, particular those which activate the transcription factor NRF2, alongside chemotherapy has shown merit in this regard in experimental models (Wang et al., 2000; Robinson et al., 2013). It may be that this approach would be of particular value in those individuals with a large tumour burden needing prolonged treatment with pre-operative chemotherapy.

In conclusion, we have developed an experimental model which demonstrates that the development of SOS in patients with CRLM is likely to be multifactorial and supports the notion that tumour-related factors may also contribute to this process.

ACKNOWLEDGEMENTS

This work was funded by a Wellcome Trust Clinical Research Training Fellowship (WT090974MA) awarded to Stuart Robinson. Steve White was funded by a Royal College of Surgeons (England) pump priming grant and a Spire Healthcare Project Grant. Derek Mann is supported by Wellcome Trust Grants WT084961MA and WT087961MA. The IVIS Spectrum was purchased through a Wellcome Trust Equipment Grant (WT087961MA). The IVIS Spectrum was purchased through a pump priming grant and a Spire Healthcare Project Grant. Derek Mann is supported by Wellcome Trust Grants WT084961MA and WT087961MA. The IVIS Spectrum was purchased through a Wellcome Trust Equipment Grant (WT087961MA).

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

REFERENCES


This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/